One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically ...

Please provide your email address to receive an email when new articles are posted on . Compared with a cohort free of kidney disease, patients with primary nephrotic syndrome were nearly 20-times ...

Roche’s phase III INShore study of Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome meets its primary endpoints: Basel Wednesday, October 29, 2025 ...

Roche (ROG: SIX) has reported positive top-line results from the Phase III INShore study of Gazyva (obinutuzumab) in children ...

The randomized, open-label INSHORE trial (ClinicalTrials.gov Identifier: NCT05627557) evaluated the safety and efficacy of obinutuzumab in children and young adults in clinical remission aged 2 to 25 ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

If approved, Gazyva/Gazyvaro could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease1 INShore is the first global phase III study ...